Back to Browse Journals » Clinical Ophthalmology » Volume 1 » Issue 4

Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

Authors Cleber A Trujillo, Arthur A Nery, Janaí­na M Alves, Antonio H Martins, Henning Ulrich

Published Date January 2007 Volume 2007:1(4) Pages 393—402

DOI

Published 10 January 2007

Cleber A Trujillo1, Arthur A Nery1, Janaína M Alves2, Antonio H Martins1, Henning Ulrich1

1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil; 2Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil

Abstract: Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects.

Keyword: anti-VEGF aptamer, pegaptanib, age-related macular degeneration

Download Article [PDF] 

Readers of this article also read:

Direct electrochemical oxidation of S-captopril using gold electrodes modified with graphene-AuAg nanocomposites

Pogacean F, Biris AR, Coros M, Lazar MD, Watanabe F, Kannarpady GK, Al Said SA Farha, Biris AS, Pruneanu S

International Journal of Nanomedicine 2014, 9:1111-1125

Published Date: 25 February 2014

Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION–EGF) for targeting brain tumors

Shevtsov MA, Nikolaev BP, Yakovleva LY, Marchenko YY, Dobrodumov AV, Mikhrina AL, Martynova MG, Bystrova OA, Yakovenko IV, Ischenko AM

International Journal of Nanomedicine 2014, 9:273-287

Published Date: 3 January 2014

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Writing 3D patterns of microvessels

Juodkazis S

International Journal of Nanomedicine 2012, 7:3701-3702

Published Date: 13 July 2012

Development of 3D in vitro platform technology to engineer mesenchymal stem cells

Hosseinkhani H, Hong P, Yu D, Chen Y, Ickowicz D, Farber I, Domb AJ

International Journal of Nanomedicine 2012, 7:3035-3043

Published Date: 29 June 2012

Medicine at nanoscale: a new horizon

Khan AU

International Journal of Nanomedicine 2012, 7:2997-2998

Published Date: 18 June 2012

Frontalis sling procedure for ocular myasthenia gravis

Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N

Clinical Ophthalmology 2012, 6:575-577

Published Date: 12 April 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009